Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 12/20 | 0.55 |
| ▸ | CLK1 | P49759 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17361106 | 1.00 | MAPKAPK2 (0.55) | MAPKAPK2CLK1GSK3BMAP3K14USP30 | |
| SCHEMBL16123414 | 0.88 | MAPKAPK2 (0.49) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL16123221 | 0.85 | MAPKAPK2 (0.59) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL16123493 | 0.82 | MAPKAPK2 (0.52) | MAPKAPK2CLK1GSK3BMAP3K14HDAC4 | |
| SCHEMBL16123368 | 0.79 | MAPKAPK2 (0.56) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL17361157 | 0.79 | MAPKAPK2 (0.49) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL16123224 | 0.79 | MAPKAPK2 (0.58) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 | |
| SCHEMBL17361152 | 0.74 | MAPKAPK2 (0.49) | MAPKAPK2CLK1GSK3BMAP3K14 | |
| SCHEMBL16123417 | 0.74 | MAPKAPK2 (0.49) | MAPKAPK2CLK1GSK3BMAP3K14 | |
| SCHEMBL17361078 | 0.74 | MAPKAPK2 (0.54) | MAPKAPK2CLK1GSK3BMAP3K14RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885CLK1 1154/4885GSK3B 260/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885CLK1 1154/4885GSK3B 260/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885CLK1 1154/4885GSK3B 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.